OLMESARTAN

Product Description

Niksan Pharmaceutical is one of the leading manufacturer, supplier and exporter of the Olmesartan. The best productmanufactured by Niksan Pharmaceutical is Olmesartan.  We manufacture, supply and export bestquality product of Olmesartan API along with Olmesartan formulations.

Niksan Pharmaceutical provides best quality product of Olmesartanin all states of India like Kerala, Punjab, Rajasthan, Telangana, UttarPradesh, Gujarat, Delhi, Tamil Nadu, Bihar, Karnataka, Jammu and Kashmir,Maharashtra, West Bengal, Odisha, Madhya Pradesh, Andhra Pradesh, Haryana  and many other states.

NiksanPharmaceutical is also manufacture and exports large quantity of Olmesartan  products in whole globe since many years incountries like Guatemala,Venezuela, Honduras, Bangladesh, Nicaragua, Ireland, El Salvador, Italy, United States , Australia, Dominican Republic, Mexico, Portugal, Canada, Chile, South Korea, Spain, United ArabEmirates, Philippines and many more countries.

Olmesartan belongs to the medicine class called angiotensin receptor blockers.Olmesartan used in the treatment of hypertension. Olmesartan decrease the highblood pressure by relaxing the smooth muscle by vasodilation.

IUPAC NAME: 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl) phenyl] phenyl} methyl)-1H-imidazole-5-carboxylic acid

CAS NO: 144689-24-7

FORMULA: C₂₄H₂₆N₆O₃

MOLECULAR MASS: 446.50 g/mol

STORAGE CONDITIONS: Store medicine in cool and dry place, awayfrom direct heat and sunlight. Do not store medicine in humid place likebathroom or kitchen. Keep away from children and pets.

HOW TO USE: Take medicine once per day by mouth. If youare using the oral liquid form, shake the container before use. Carefullymeasure the liquid dosage form.

HOW OLMESARTAN WORKS: Olmesartaninhibits the high blood pressure by binding with angiotensin II receptor.Angiotensin II cause vasoconstriction so by inhibiting the enzyme Olmesartancause vasodilation of the smooth muscle and by this blood flow increases andprevents hypertension.

PHARMACOKINETICS: Olmesartan rapidly absorbed IN GI trackafter the oral administration with the bioavaibility of 4.5% to 28.6%. Almost99% of Olmesartan binds with the blood plasma albumin. The half-life ofOlmesartan is 10-15hours. Approximately 10-16% of Olmesartan eliminated throughurine.

SIDE EFFECTS: Common side effects of Olmesartan arelightheadness and dizziness. Other side effects like fainting, high potassiumblood level, signs of kidney problem. Some other rare reactions like skin rash,itching, swelling of skin, dizziness, trouble in breathing.

PRECAUTIONS: Before talking the Olmesartan medicine,tell your doctor if you are allergic to Olmesartan. Tell your doctor about yourmedical history like liver disease, kidney disease, dehydration or anyrespiratory problem. This medicine makes you dizzy so kindly avoid takingalcohol and cannabis products. Also avoid driving or operating machineriesbecause Olmesartan makes you dizzy.

CDSCO APPROVAL: FDCof Olmesartan Medoxomil (20mg/40mg/40mg) + Hydrochlorthiazide(12.5mg/12.5mg/25mg)approved by CDSCO in India in 02.12.2005,

Amlodipine Besilate IP eq.to Amlodipine 10mg/5mg/5mg/5mg/2.5mg +Olmesartan Medoxomil 40mg/40mg/20mg/5mg/5mg + Hydrochlorothiazide IP 25mg/12.5mg/12.5mg/12.5mg/12.5mgTablet 23.11.2011

Olmesartan Medoxomil (20mg) + Amlodipine Besylate (5mg) Tabletapproved by CDSCO in India in 15.10.2007,

Metoprolol succinate ER 25mg+50mg + Olmesartan 20/20mg approved byCDSCO in India in 19.07.2010,

Olmesartan 40mg + Amlodipine 5mg (Additional Strength) approved byCDSCO in India in 09.08.2010,

Olmesartan medoximil-20mg + Ramipril-5mg. Tablet approved by CDSCOin India in 12.6.2007,

Olmesartan (20/40mg) + Atorvastatin 5/10/20mg film coated tablets approvedby CDSCO in India in 27.10.2009,

Olmesartan + Ramipril (40mg + 5mg) tablets (Additional Strength)approved by CDSCO in India in 15.09.2008,

Olmesartan (as Medoxomil) 10mg (addl. Strength) approved by CDSCOin India in 18.05.2006,

Olmesartan Medoxomil (5mg/20mg/40mg) Tablet approved by CDSCO inIndia in 21.07.2005,

Olmesartan 40mg + Hydrochlorthiazide 25mg tablet (addl. Strength)approved by CDSCO in India in 28.06.2006.

FORMULATIONS AVAILABLE IN MARKET:

Olmesartan Medoxomil 5mg tablets

Olmesartan Medoxomil20mg tablets

Olmesartan Medoxomil 40mg tablets

Olmesartan Medoxomil 10mg tablets

Olmesartan Medoxomil 20mg + amlodipine 5mg tablets

Metoprolol succinate ER 25mg+ Olmesartan 20mg tablets

Metoprolol succinate ER 50mg + Olmesartan 20mg tablets

Olmesartan + Ramipril (40mg + 5mg) tablets

Olmesartan 40mg + Hydrochlorthiazide 25mg tablets

Olmesartan 40mg + Amlodipine 5mg tablets

Note: Product protected by valid patents are notoffered for sale in countries where such patents are still valid and itsliability is at Buyers Risk.

REFERENCES:

www.webmd.com

https://pubchem.ncbi.nlm.nih.gov

https://go.drugbank.com

https://cdscoonline.gov.in

https://www.wikipedia.org/

https://www.drugs.com

https://www.zaubacorp.com

https://www.practo.com/consult